Buprenorphine Treatment:
A Training for Multidisciplinary
Addiction Professionals
August 16, 2005
Purpose
The primary goal of this training is to create awareness about buprenorphine among multi-disciplinary addiction professionals. The
materials include information designed to increase motivation for bringing buprenorphine to local communities, as well as information
about what to expect when someone is treated with this medication. Additionally, materials discuss legislation that permits officebased buprenorphine treatment, the science of addiction, the mechanism of buprenorphine, patient selection issues, and various patient,
counseling, and therapeutic issues.
The Blending Initiative
In order to disseminate information to the addiction treatment field, The National Institute on Drug Abuse (NIDA) has created a
partnership with the Addiction Technology Transfer Center (ATTC) Network funded by SAMHSA’s Center for Substance Abuse
Treatment. The 14 regional ATTCs and the ATTC National Office provide specialized training and technical assistance to the field in
order to further develop evidence-based practices and enhance the skills of the substance abuse treatment workforce.
Through the NIDA-SAMHSA Blending Initiative, Blending Teams composed of NIDA researchers and ATTC representatives were
created to design dissemination strategies. This training was designed to provide a broad overview of the medication buprenorphine,
its effects, and the role of non-physician practitioners in providing and supporting the treatment of individuals receiving this
medication.
Objectives
Upon completion, participants involved in the buprenorphine training will be able to:
1. Recognize the mechanism of buprenorphine.
2. Discuss Opioids 101: Basic information about opioid dependence;
3. Review Buprenorphine 101: Overview of the medication and its use;
4. Identify patients for buprenorphine treatment;
5. Coordinated Care; and
6. Demonstrate counseling of buprenorphine patients.
*An annotated bibliography and research articles providing additional information about this exciting new treatment for opioid
dependence.
Date and Location
The training will be held August 16, 2005, at the Metro Technology Center, 1900 Springlake Drive, Carousel Room, Oklahoma City.
From Interstate 35, take the 36th Street exit and travel west to Martin Luther King Blvd., turn right (north) and you will immediately
see the Metro Tech to your left. Parking is on the south and north side of the main building on Martin Luther King Boulevard.
Faculty
Jan Campbell, M.D., is one of 11 doctors in the state of Kansas who is authorized to prescribe buprenorphine. Dr. Campbell is a
board-certified general psychiatrist with sub-certification in addiction from the American Board of Psychiatry and Neurology. She has
worked in substance abuse treatment in the Kansas City area since 1986, and has been a faculty member at the University of Kansas
Medical Center since 1982. Dr. Campbell has experience in both psychopharmacologic and multi-site substance abuse treatment trials
and in the management of treatment programs.
Donald McMillan, Ph.D., is a researcher at the University of Arkansas for Medical Sciences (UAMS). His research is directed
toward an understanding of the environmental, historical and genetic factors that underlie the acquisition, maintenance and reversal of
drug and alcohol abuse. He is known inter-nationally for his expertise on drug abuse treatment and prevention. Dr. McMillan is the
retired chairperson of Alcoholism and Drug Abuse Prevention in the Department of Pharmacology and Toxicology.
Continuing Education Credits
Continuing education credit hours have been approved through the Oklahoma State Board of Licensed Social Workers and the
Licensed Professional Counselors Committee. Participant evaluation forms must be submitted in order to receive continuing education
credit and a certificate of attendance. Certificates of attendance will be distributed at the end of the training. If you need to leave early,
please go to the registration desk to pick up your certificate reflecting your hours of attendance. There will be a $5.00 charge for
reissuing of certificates.
Special Accommodations
Sign interpreters and/or other special accommodations required by disabled participants will be available upon advance request (please
allow one week’s notice). Please indicate on the registration form the type of special accommodations, if any, you require. For
requests, call 405-522-8300.
Program Schedule
8:00 a.m. – 9:00 a.m.
9:00 a.m. – 9:15 a.m.
9:15 a.m. – 10:15 a.m.
10:15 a.m. – 10:45 a.m.
10:45 a.m. – 11:00 a.m.
11:00 a.m. – 11:45 a.m.
11:45 p.m. – 1:00 p.m.
1:00 a.m. – 1:30 p.m.
1:30 p.m. – 2:15 p.m.
2:15 p.m. – 2:30 p.m.
2:30 p.m. – 3:00 p.m.
3:00 p.m. – 4:15 p.m.
4:15 p.m. – 4:30 p.m.
Registration
Opening Remarks and Introductions of Trainers
Module I: Introduction
Module II: Opioids 101
Break
Module III: Buprenorphine 101
Lunch
Module IV: Identification of Patients for Buprenorphine Treatment
Module V: Coordinated Care
Break
Module V: Coordinated Care (continued)
Module VI: Counseling Buprenorphine Patients
Feedback / Discussion / Evaluation
Seminar Fees
The Buprenorphine Awareness training curriculum and the training itself, is funded by the National Institute of Drug Abuse (NIDA)
and the Substance Abuse and Mental Health Services Administration’s Center for Substance Abuse Treatment (CSAT) through the
ATTC Network and the Mid-America Addiction Technology Transfer Center (ATTC) at no charge to participants.
Lodging
The following hotel is conveniently located for seminar participants who need overnight accommodations. Let them know you are
attending the Department of Mental Health and Substance Abuse Services training.
Oklahoma City:
Holiday Inn Hotel and Suites
6200 N. Robinson
Oklahoma City, OK. 73112
405-843-5558
$66.00/per night
****Complete the form below and mail it to:
Seminar Coordinator
Human Resource Development Division
Institute for Mental Health and Substance Abuse Education and Training
2401 NW 23rd St., Suite 82
Oklahoma City, OK 73107
****Or fax registration to 405/522-8320.

Registration:
Buprenorphine Treatment: August 16, 2005
LCSW

Name ________________________________________________________________________
Home Number_________________________________________________________________
Occupation or Job Title__________________________________________________________
Place of Employment____________________________________________________________
Address_______________________________________________________________________
City, State, Zip_________________________________________________________________
Daytime Phone_________________________________________________________________
E-Mail Address_________________________________________________________________
Continuing Education Credit Requested:

LPC/LMFT
CADC
Psychologist
Student
Other________

RN/LPN
Require
accommodations
special
as
follows:
____
____
____
____
____
____
____
_______